CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.
Breast Cancer|Circulating Tumor Cell
DEVICE: GILUPI CellCollector®
invasive disease-free survival (iDFS), Invasive disease-free survival time is defined as the time from date of randomization until the first occurrence of invasive disease recurrence, distant metastasis and death from any cause., From surgery until time of event up to 3 years
pathological complete response (pCR), ypT0 ypN0, ypT0/is ypN0, ypT0 or ypT0/is, at surgery|overall Survival (OS), Overall survival is defined as the time from randomization to death from any cause., From surgery until time of event up to 3 years
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.